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Appearance of dyskinesia is a common problem of long-term L-DOPAtreatment in Parkinson’s disease patients
and represents a major limitation for the pharmacological management of the motor symptoms in advanced
disease stages.We have recently demonstrated that dopamine released from serotonin neurons is responsible
for L-DOPA-induced dyskinesia in 6-hydroxydopamine (6-OHDA)-lesioned rats, raising the possibility that
blockade of serotonin neuron activity by combination of 5-HT1A and 5-HT1B agonists could reduce L-DOPA-
induced dyskinesia. In the present study, we have investigated the efficacy of 5-HT1A and 5-HT1B agonists to
counteract L-DOPA-induced dyskinesia in 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP)-treated ma-
caques, the gold standard modelof Parkinson’s disease.In addition, we have studied the abilityof this treatment
to prevent development of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. The results demonstrate the
existence of a potent synergistic effect between 5-HT1A and 5-HT1B agonists in their ability to dampen L-DOPA-
induced dyskinesia in the MPTP-treated macaques. Sub-threshold doses of the drugs, which individually pro-
duced no effect, were able to reduce the abnormal involuntary movements by up to 80% when administered in
combination, without affecting the anti-parkinsonian properties of L-DOPA. Furthermore, chronic administra-
tion of low doses of the 5-HT1 agonists in combination was able to prevent development of dyskinesia, and
reduce the up-regulation of FosB after daily treatment with L-DOPA in the rat 6-OHDA model. Our results
support the importance of a clinical investigation of the effect of 5-HT1A and 5-HT1B agonists, particularly in
combination, in dyskinetic L-DOPA-treated Parkinson’s disease patients.
Keywords: L-DOPA; Dyskinesia; Parkinson’s disease; Serotonin agonists; MPTP monkeys
Abbreviations: AIMs=abnormal involuntary movements; AUC=area under the curve; DA=dopamine; MPTP=1-methyl-
4-phenyl1,2,3,6-tetrahydropyridine; 6-OHDA=6-hydroxydopamine; PSD=post-synaptic density; s.c.=subcutaneous;
TIF=Triton X-100-insoluble fraction
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Introduction
The appearance of dyskinesias represents the most trouble-
some side effect of long-term L-DOPA administration in
Parkinson’s disease patients and limits the use of L-DOPA in
the advanced disease stage (Obeso et al., 2000; Rascol et al.,
2000; Ahlskog and Muenter, 2001). In early stages of the
disease, it is generally assumed that L-DOPA acts by being
taken up into spared dopaminergic neurons and terminals,
where it is converted to dopamine (DA), stored into synaptic
vesicles and released in a physiologically regulated manner
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 (Cenci and Lundblad, 2006). As the dopaminergic degenera-
tion progresses, fewer and fewer DA terminals can contribute
to the conversion of peripheral administered L-DOPA. In this
situation, other neuronal and non-neuronal cell types are
suggested to play a role in DA production (Melamed et al.,
1980; Hefti et al., 1981;). Among these, the serotonin neurons
represent an interesting element because they express
aromatic amino acid decarboxylase and vesicular monoamine
transporter 2, which are responsible for conversion of
L-DOPA to DA and storage of DA into synaptic vesicles,
respectively (Arai et al., 1994; Peter et al., 1995). Several
studies have shown that the serotonin neurons have the
capacity to store and release DA after peripheral administra-
tion of L-DOPA, both in vivo and in vitro (Ng et al., 1970,
1971; Hollister et al., 1979). Tanaka and co-workers (1999)
have shown that lesion of the serotonin system by
intraventricular administration of the specific toxin 5,7-
dihydroxytryptamine (5,7-DHT) reduced L-DOPA-derived
extracellular DA by about 80% in hemiparkinsonian rats.
A similar reduction in extracellular striatal DA level was also
obtained following co-administration of the 5-HT1A agonist
( )-8-OH-DPAT with L-DOPA (Kannari et al., 2001), which
also reduced up-regulation of prodynorphin and glutamic
acid decarboxylase in the DA-denervated striatum, both of
which are established markers of L-DOPA-induced motor
complications (Tomiyama et al., 2005).
We have recently demonstrated a causal link between the
DA released from the serotonin neurons and the appear-
ance of abnormal involuntary movements (AIMs) in the rat
6-hydroxydopamine (6-OHDA) model (Carta et al., 2007).
In these experiments, removal of the serotonin innervation
by intraventricular injection of 5,7-DHT, or pharmacolog-
ical silencing of the release from these neurons by a com-
bination of 5-HT1A and 5-HT1B receptor agonists, resulted
in a near-complete suppression of L-DOPA-induced dyski-
nesias in L-DOPA-primed 6-OHDA-lesioned rats. In
addition, we showed that serotonin neuron transplants
increased the pro-dyskinetic effect of L-DOPA by providing
a 2- to 3-fold increase in the serotonin innervation of the
host striatum and thus a possible additional source of
dysregulated DA release (Carlsson et al., 2007). These
results suggest the DA released from serotonin terminals is
the main pre-synaptic determinant of L-DOPA-induced
dyskinesia in the rat Parkinson’s disease model.
These results in dyskinetic rats suggested a potential use of
5-HT1A and 5-HT1B agonists, particularly in combination, for
the treatment of L-DOPA-induced dyskinesia in Parkinson’s
disease patients. However, preclinical development of this
approach required further validation in primate models
of Parkinson’s disease, such as the 1-methyl-4-phenyl
1,2,3,6-tetrahydropyridine (MPTP)-treated macaque. In the
present study, we have therefore tested the efficacy of acute
challenges with the 5-HT1A and 5-HT1B agonists, individually
and in combination, to counteract L-DOPA-induced dyski-
nesia in dyskinetic MPTP-treated macaques. In addition, the
effect of chronic administration of 5-HT1A and 5-HT1B
agonists was tested on the development of L-DOPA-induced
dyskinesia in 6-OHDA-lesioned rats.
Materials and Methods
Monkey studies
Housing
Six female cynomolgus monkeys (Macaca fascicularis, Xierxin,
Beijing, PR of China) were used. Animals were 5-years old and
were previously treated with other drugs. However, 2 month
wash-out with daily exposure to L-DOPA was undertaken to avoid
possible interactions. They were housed in individual primate
cages under controlled conditions of humidity, temperature and
light (12h light/12h dark cycle, lights on at 8.00a.m.); food and
water were available ad libitum. Animal care was supervised by
veterinarians skilled in the healthcare and maintenance of non-
human primates. Experiments were carried out in accordance with
European Communities Council Directive of November 24, 1986
(86/609/EEC) for care of laboratory animals.
Experimental parkinsonism and dyskinesia
Experiments were conducted according to previously published
procedures and methods (Bezard et al., 2003; Aubert et al., 2005;
Guigoni et al., 2005). Monkeys received once daily i.v. injections
of MPTP hydrochloride (0.2mg/kg) until they displayed parkin-
sonian symptoms (mean number of injections=15 1) (Bezard
et al., 2001a). It took an average of 8 weeks for the bilateral
parkinsonian syndrome to stabilize (i.e. consistent disability score
over 2 consecutive weeks—median score=8.5 with 7–10 range).
Monkeys were then treated chronically with twice daily oral
administration of Modopar (Roche, Basel, Switzerland, L-DOPA/
carbidopa, ratio 4:1) for 6 months at a tailored dose designed to
fully reverse the parkinsonian features (L-DOPA/cabidopa dose
ranging between 15mg/kg and 20mg/kg, 3.7mg/kg and 5mg/kg,
respectively) and developed dyskinesia.
Experimental design
L-DOPA/carbidopa (or its vehicle) was administered orally con-
comitantly with a subcutaneous (s.c.) administration of either ve-
hicle, the 5-HT1A agonist ( )-8-Hydroxy-2-dipropylaminotetralin
hydrobromide [( )8-OH-DPAT, TOCRIS, UK] and/or the 5-HT1B
agonist, CP-94253 (TOCRIS) in the animal’s home cage
(Bezard et al., 2003; Gold et al., 2007). The animals were
immediately transferred to an observation cage (dimensions—
1.1m 1.5m 1.1m) for a 250min behavioural assessment
(see below). Ten different treatments were employed; vehicle–
vehicle, L-DOPA/carbidopa (dose ranging between 15mg/kg and
20mg/kg and 3.7mg/kg and 5mg/kg, respectively) vehicle, L-DOPA/
carbidopa-8-OH-DPAT (0.05mg/kg and 0.1mg/kg), L-DOPA/
carbidopa-CP-94253 (1.75mg/kg and 2.5mg/kg) and all combina-
tions of L-DOPA/carbidopa-8-OH-DPAT-CP-94253. The 10 differ-
ent treatments were randomly tested in each animal with a 3day
wash-out period in between.
Behaviouralassessment
A battery of behavioural tests was performed as previously described
(e.g. Bezard et al., 2003; Guigoni et al., 2005a,b; Gold et al., 2007).
A quantitative assessment of locomotor activity using computer-
based passive infrared activity monitors (Excalibur, modified by the
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 Central Electronic Workshop, University of Manchester)
was obtained every 5min for 250min (Bezard et al., 2003; Gold
et al., 2007).
Non-parametric measures based on range of movement,
bradykinesia and posture scales were made; parkinsonian condi-
tion (and its reversal) was assessed on a parkinsonian monkey
rating scale (Imbert et al., 2000) by post hoc analysis of video
recordings by observers blinded to the treatment, in 10min
observation periods every 30min for 250min, as previously
described (e.g. Bezard et al., 2003; Guigoni et al., 2005a,b).
A score of 0 corresponds to a normal animal and a score above 6
to a parkinsonian animal.
The severity of dyskinesia was rated using the dyskinesia disability
scale (Bezard et al., 2003; Gold et al., 2007) by post hoc analysis of
video recordings, in 10min observation periods every 30min for
250min. Both choreic (hyperkinetic, purposeless dance-like move-
ments) and dystonic (sustained, abnormal muscle contractions)
components of dyskinesia were rated: 0=dyskinesia absent;
1=mild, fleeting and rare dyskinetic postures and movements;
2=moderate, more prominent abnormal movements, but not
interfering significantly with normal behaviour; 3=marked,
frequent and, at times, continuous dyskinesia intruding on the
normal repertoire of activity; or 4=severe, virtually continuous
dyskinetic activity replacing normal behaviour and disabling to the
animal. All scales have been validated for inter- and intra-variability
and differences in rating were discussed regularly to eliminate
observer idiosyncrasy (Taylor et al., 1994). For ethical and
experimental reasons, animals were not killed at the end of
behavioural experiments. However, historical data obtained with
animals submitted to the very same regimen of MPTP and L-DOPA
administrations have shown extreme lesions of the nigrostriatal
pathway and comparable extent and pattern of denervation among
the animals (Guigoni et al., 2005b).
Rat studies
Housing
A total of 140 adult female Sprague–Dawley rats weighing
225–250g were used in the present study (B&K Universal,
Stockholm, Sweden). The animals were housed under a 12h
light/12h dark cycle with free access to water and food. All
experiments were performed according to the regulations set by
the Ethical Committee for use of Laboratory animals at Lund
University.
Experimental parkinsonism
All 6-OHDA injections were conducted under anesthesia induced
by an injectable 20:1 mixture of Fentanyl and Dormitor
(Apoteksbolaget, Sweden) using a stereotaxic frame (Stoelting,
Wood Dale, Illinois) with an attached Hamilton syringe. The
animals received 6-OHDA (Sigma-Aldrich AB, USA) injection
into the medial forebrain bundle (MFB) (14mg free base in 4mlo f
saline containing 0.02% ascorbic acid) in order to achieve a
complete lesion of the nigrostriatal pathway at the following
coordinates (relative to bregma, see Paxinos and Watson (1998):
AP:  4.4mm, ML:  1.2mm, DV:  7.8mm. The toothbar was set
at  2.4mm. Injection speed was 1.0ml/min and the syringe was
kept in place for an additional 3min before it was slowly
retracted.
Experimental design
Three weeks after 6-OHDA injection, the rats were screened
behaviourally in the amphetamine-induced rotation test
(2.5mg/kg i.p.). Animals exhibiting 56 full body turns/min
towards the side of DA deficiency were included in the study.
Animals were then allocated into two well-matched sub-groups
(according to the amphetamine rotation) and received daily
treatment with either L-DOPA methyl ester (6mg/kg i.p. plus
benserazide 10mg/kg) individually, or in combination with the
5-HT1A agonist ( )8-OH-DPAT and the 5-HT1B agonist CP-
94253 given s.c. at the same time of L-DOPA, for two weeks. At
the end of this treatment (treatment period 1), animals received a
low dose of apomorphine (0.02mg/kg, s.c.) and tested for
apomorphine-induced AIMs in order to investigate the sensitiza-
tion state of the DA receptors. Treatments were then switched so
that animals receiving L-DOPA only during treatment period 1
now received L-DOPA+5-HT1 agonists, while animals previously
treated with L-DOPA+5-HT1 agonists were treated only with
L-DOPA for an additional two weeks (treatment period 2).
Animals were injected daily and tested every second day for
L-DOPA-induced dyskinesia throughout the experimental periods
1 and 2 and then sacrificed for HPLC analysis of DA, serotonin
and metabolites. Additional groups of animals were treated in an
identical way and sacrificed at the end of the treatment period 1
for western blotting analysis and FosB immunostaining.
HPLC measurements
All animals were killed and striata were rapidly dissected out, frozen
on dry ice and stored in  80 C freezer until analysis. At the time of
the analysis, tissue was homogenized in 0.1M perchloric acid and
centrifuged at 10000r.p.m. for 10min before filtering though
minispin filters for additional 3min at 10000r.p.m. The tissue
extracts were then analysed by HPLC as described earlier (Carta
et al., 2006) with minor modifications. Briefly, 25ml of each sample
were injected by a cooled autosampler (Midas, Spark, Holland) into
an ESA Coulochem III coupled with an electrochemical detector.
The mobile phase (sodium acetate 5g/l, Na2-EDTA 30mg/l, octane-
sulfonic acid 100mg/l, methanol 10%, pH 4.2) was delivered at a
flow rate of 500ml/min to a reverse phase C18 column (4.6mm Ø,
150mm length, Chrompack, Middleburg, The Netherlands). Peaks
of DA, serotonin and metabolites were processed by the Azur
Chromatographic Software (Dataly, France).
Amphetamine-induced rotation
Amphetamine-induced rotation was performed 3 weeks after
the 6-OHDA injection to evaluate the extent of the DA lesion.
Right and left full-body turns were recorded over 90min,
using automated rotometer bowls (AccuScan Instrument Inc.,
Columbus, Ohio), following an i.p. injection of 2.5mg/kg of
d-amphetamine sulphate (Apoteksbolaget, Sweden). The data are
expressed as net full-body turns per minute, where rotation
towards the side of the lesion was given a positive value.
L-DOPA- and Apomorphine-induced dyskinesia
In all tests, the AIMs were evaluated according to the rat
dyskinesia scale described in detail previously (Lee et al., 2000;
Lundblad et al., 2002). Briefly, the animals were placed individ-
ually in transparent plastic cages without bedding material and
scored every 20min following the injection of L-DOPA for the
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 entire time course of dyskinesias (about 120min). The AIMs were
classified into four subtypes according to their topographic
distribution as forelimb (Li), orolingual (Ol) axial (Ax) and
locomotive (Lo) behaviours. The forelimb and orolingual
dyskinesia are predominantly seen as hyperkinesia, while the
axial dyskinesia is essentially of a dystonic type. The locomotive
dyskinesia was expressed as circling movements away from the
lesioned side. Enhanced manifestations of normal behaviours, such
as grooming, gnawing, rearing and sniffing were not included in
the rating. The severity of each AIM subtype was assessed using
scores from 0 to 4 (1: occasional, i.e. present550% of the time; 2:
frequent, i.e present 450% of the time; 3: continuous, but inter-
rupted by strong sensory stimuli; 4: continuous, not interrupted
by strong sensory stimuli).
Dyskinesias were also evaluated after apomorphine injection
(0.02mg/kg, dissolved in saline containing 0.002% ascorbic acid;
Apoteksbolaget, Sweden). Here, scoring was performed every
10min using the same rating scale as for the L-DOPA-induced
dyskinesias. The data are presented as integrated scores, area
under the curve (AUC) in a raw data plot of total Ax+Li+Ol
AIM scores (total AIMs interval of observation: 20 for
L-DOPA; 10 for apomorphine).
Activity test
Locomotor activity was assessed (at day 3 of the treatment period 1)
in open-field chambers, each equipped with a 16 16 infrared
photobeam system (dimensions 40.6cm 40.6 cm 38.1cm) using
the Flex-Field Software system (San Diego Instruments, San Diego,
CA). Animals were habituated for 1h before the drugs were injected
and the measurements begun.
Stepping test
The stepping test (Schallert et al., 1992) was performed as previously
described (Kirik et al., 2001) with little modifications. Briefly, the rat
was held by the experimenter fixing its hindlimbs with one hand and
the forelimb not to be monitored with the other, while the
unrestrained forepaw was touching the table. The number of
adjusting steps was counted, while the rat was moved sideways along
the table surface (90cm in 5s), in the forehand and backhand
direction, for both forelimbs, and the average of the steps in the two
directions was considered. Performance of the animals in the
stepping test was assessed during treatment period 1 (after training
sessions and reach of a stable performance) in the L-DOPA+5-HT1
agonists-treated group and in a group of naı ¨ve rats, after
administration of L-DOPA+5-HT1A+5-HT1B agonists or L-DOPA
only, respectively. On the day of the test (day 5 of treatment
period 1) L-DOPA+5-HT1 agonists-treated and naı ¨ve rats were
tested twice in baseline condition and two more times 60min after
administration of the drugs. Values are reported as an average of the
two sessions on and off drug.
Estimation of FosB-positive cell numbers in striatum
An additional group of animals was subjected to the treatment
period 1, as above. Treatment with 5-HT1 agonists resulted in a
significant protection from dyskinesia in this group as well
(mean SEM at the last treatment: 421 130 versus 56 28 in
L-DOPA only and L-DOPA+5-HT1 agonists, respectively).
Animals were sacrificed 48h after the last treatment, as previously
described (Carlsson et al., 2005), the brains were removed and
processed for FosB immunostaining. Briefly, the brains were cut
into 16mm thickness on a cryostat (HM500M, Microm, Walldorf,
Germany) and the sections were mounted on plus-charged glass
slides (Superfrost +; Electron Microscopy Sciences, PA, USA).
Striatal sections were processed for FosB immunohistochemistry,
while additional striatal and midbrain sections were processed for
tyrosine hydroxylase (TH) immunohistochemistry to verify the
dopaminergic lesion. Sections were fixed for 30min in 10%
formalin and further rinsed with 3 KPBS+0.25% Triton-X
(KPBS/T). After pre-incubation for 1h with 5% NHS (normal
horse serum) in KPBS/T, slides were incubated overnight in room
temperature with the corresponding primary antibody: FosB
(1:15000; goat polyclonal IgG; SC-48X; Santa Cruz, CA, USA)
or TH (1:2000; mouse IgG; Chemicon, Millipore, USA, MAB
318). This was followed by 1h incubation with the corresponding
biotinylated secondary antibody (1:250, horse-a-goat, BA9500 or
horse-a-mouse, BA2001; Vector Laboratories, Burlingame, CA,
USA). After this incubation the slides were further incubated for
1h in avidin-biotin-peroxidase solution (ABC Elite; Vector
Laboratories) and visualized using the chromogen 30,30-diamino-
benzidine and 0.01% H202. Finally, the sections were dehydrated
in ascending alcohol solution, cleared in xylene and coverslipped
with Depex.
Two high-resolution images were captured for the FosB
quantification, corresponding to +0.7mm and  0.3mm from
bregma, using a Scanscope GL system with imagescope v8.2
software. The images were then imported into Canvas software
and positive cells were marked in the whole striatum to give the total
number of cells per section, as well as number of cells restricted
to the lateral part of the striatum, which was defined as one-third of
the length of the striatum in each section. Values are expressed as
total number of positive cells in the two sections considered.
Western blot analysis of NMDA composition in the
post-synaptic density
To investigate NMDA receptor composition at the level of the post-
synapticdensity (PSD),anadditional groupofanimalswassubjected
to the treatment period 1, as above. Treatment with 5-HT1 agonists
resulted in a significant protection from dyskinesia in this group as
well (mean SEM at the last treatment: 607 23 versus 27 19 in
L-DOPA only and L-DOPA+5-HT1 agonists, respectively). After
the treatment period 1, animals were sacrificed 1h after the last
treatment, and striata analysed for NMDA receptor composition and
distribution by western blotting after sequential centrifugation to
separate different cellular compartments.
Subcellular fractionation was performed as reported previously
with minor modifications (Gardoni et al., 2001). Striata were
homogenized in 0.32M ice-cold sucrose containing the following
(in mM): 1 HEPES, 1 MgCl2, 1 EDTA, 1 NaHCO3 and 0.1 PMSF, at
pH 7.4, in the presence of a complete set of protease inhibitors
(Complete; Roche Diagnostics, Basel, Switzerland) and phospha-
tases inhibitors (Sigma, St Louis, MO, USA). The homogenized
tissue was centrifuged at 1000g for 10min. The resulting super-
natant (S1) was centrifuged at 13000g for 15min to obtain a crude
membrane fraction (P2 fraction). The pellet was resuspended in
1mM HEPES plus CompleteTM in a glass–glass potter and
centrifuged at 100000g for 1h. The pellet (P3) was resuspended
in buffer containing 75mM KCl and 1% Triton X-100 and
centrifuged at 100000g for 1h. The supernatant was stored and
referred as Triton X-100-soluble fraction (S4). The final pellet (P4)
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 was homogenized in a glass–glass potter in 20mM HEPES. Then, an
equal volume of glycerol was added, and this fraction, referred as
Triton X-100-insoluble fraction (TIF), was stored at  80 C until
processing. TIF was used instead of the classical PSD because the
amount of the starting material was very limited. The protein
composition of this preparation was, however, carefully tested for
the absence of pre-synaptic markers (i.e. synaptophysin) (Gardoni
et al., 2001). Similar protein yields were obtained in TIF purified
from striata of all experimental groups, and the same amount of TIF
protein was applied to SDS–PAGE and electroblotted for all
samples. Nitrocellulose papers were blocked with 10% albumin in
Tris-buffered saline (TBS) and then incubated for 2h at room
temperature with the primary antibodies: NR2A (diluted 1:1000),
NR2B (diluted 1:1000), PSD-95 (diluted 1:2000), SAP97 (diluted
1:1000), in 3% albumin in TBS. After extensive rinsing in TBS/
0.1% Tween-20, the nitrocellulose papers were then incubated with
horseradish peroxidase–conjugated secondary antibodies [goat anti-
rabbit for poly-clonal antibodies, diluted 1:10000 (Pierce,
Rockford, IL, USA); goat anti-mouse for monoclonal antibodies,
diluted 1:20000 (Pierce)], and then the antigen–antibody complex
was revealed by enhanced chemiluminescence (ECL; Amersham
Biosciences, Little Chalfont, UK).
Statistical analysis
Group comparisons were performed for the rat experiments using
Mann–Whitney for analysis of dyskinesias and stepping test, and
Kruskal–Wallis followed by Mann–Whitney for locomotor activity.
One-way analysis of variance (ANOVA) was used for analysis of
FosB and NR2B quantifications, followed by Bonferroni post doc
test. The Friedman non-parametric repeated measures analysis of
variance, followed by Dunn’s multiple comparisons test, was used
to analyse the primate data, except for the activity data, which
were analysed by ANOVA followed by Bonferroni. Statistics
analysis was performed using SigmaStat statistical software version
2.0 for the rat experiments and the STATA program (Intercooled
Stata 9.0, Stata Corporation, College Station, TX, USA) for the
primate experiment.
Results
Effect of serotonin receptor agonists on
L-DOPA-induced dyskinesia in MPTP-treated
macaques
To date, the MPTP-treated macaque represents the gold
standard model of Parkinson’s disease and shares several
features with the disease in humans. Whether the
serotonergic system plays an important role in dyskinesia
manifestations after L-DOPA administration in this model
is still an open issue. To investigate this point, six
dyskinetic L-DOPA-primed MPTP-treated macaques were
employed in this experiment. Each animal was subjected to
injection of L-DOPA (at the minimal dose producing the
maximal anti-parkinsonian effect), alone or together with
the 5-HT1A and 5-HT1B agonists, individually and in
combination. Two doses of the agonists were tested.
Dyskinesia and parkinsonism were evaluated according to
a modified rating scale, as previously described, and motor
activity was measured by an automated system (Bezard
et al., 2001b, 2003).
As shown in Fig. 1B, the 5-HT1A agonist ( )-8-OH-DPAT
at 0.05mg/kg and 0.1mg/kg dose produced a dose-dependent
reduction of L-DOPA-induced dyskinesia, which was sig-
nificant at the higher dose (about 70% reduction in the
AUC). Importantly, this effect was not accompanied by any
reduction in the anti-parkinsonian action of L-DOPA
(Fig. 1A). The 5-HT1B agonist CP-94253, in contrast, failed
to reduce L-DOPA-induced dyskinesia at any of the doses
tested (1.75mg/kg and 2.5mg/kg). CP-94253, however, was
able to potentiate the effect of ( )-8-OH-DPAT (Fig. 1G). In
line with our previous report in rats, we observed a synergistic
effect between the two drugs. This was evident at doses of
0.05mg/kg ( )-8-OH-DPAT plus 2.5mg/kg CP-94253,
which individually produced no or only a minor effect. At
these doses, combination of the agonists was able to reduce
dyskinesia by up to 80% (in the AUC) without any significant
worsening of the parkinsonian score compared to L-DOPA-
only (Fig. 1F and G). At higher doses, combination of the
agonists was able to produce a near-complete abolishment of
dyskinesia (about 95% reduction in the AUC). This effect,
however, was accompanied by a 70% increase in the
Parkinson’s disease score compared with L-DOPA only
(corresponding to 28% reduction in the anti-parkinsonian
efficacy of L-DOPA). Further confirming this effect is
the reduction in L-DOPA-induced motor activity (Fig. 1C
and H). One should, however, be careful in interpreting
locomotor activity counts, as they encompass both the
normal and abnormal movements (Bezard et al., 2003; Gold
et al., 2007). A reduction of the hyperkinetic component of
dyskinesia or of dyskinesia themselves would thus reduce the
number of counts (Fig. 1C—0.1mg/kg ( )-8-OH-DPAT;
Fig. 1H—0.05mg/kg ( )-8-OH-DPAT plus 2.5mg/kg CP-
94253 and 0.1mg/kg ( )-8-OH-DPAT plus 1.75mg/kgCP-
94253) but a larger decrease (e.g. Fig. 1H—0.1mg/kg
( )-8-OH-DPAT plus 2.5mg/kg CP-94253) also reflects the
reduction of the anti-parkinsonian efficacy of L-DOPA. For a
detailed highlight at peak dose dyskinesia, the effect of the
agonists on Parkinson’s disease (Fig. 1D and I) and LID
(Fig. 1E and J) scores are also reported at the 80min
observation time point.
Effect of chronic administration of 5-HT1A
and 5-HT1B agonists on the development of
L-DOPA-induced dyskinesia and therapeutic
efficacy of L-DOPA
The optimal anti-dyskinetic compound would be given in a
chronic or sub-chronic fashion. We therefore questioned
whether prolonged administration of the serotonin agonists
could prevent development of dyskinesia in naı ¨ve animals
or provide a long-lasting control of the side effect of
L-DOPA once dyskinesias have been established. Ethical,
practical and financial reasons make such a study very
difficult to be performed in monkeys and we therefore used
5-HT 1A and 5-HT1B agonists for dyskinesia Brain ( 2 0 0 8 ) P a g e5o f1 5
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
6
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Fig. 1 5-HT 1A and 5-HT1B agonists effect on L-DOPA-induced dyskinesia in the MPTP-treated macaque. (A)5- H T 1A (( )-8-OH-DPAT;
0.05 mg/kg and 0.1mg/kg) and 5-HT1B (CP-94253; 1.75mg/kg and 2.5mg/kg) agonists in combination with L-DOPA had no negative impact
upon parkinsonian disability score (as for panels B, F and G, median scores are shown without range for readability purpose, Fr=7 . 964;
P=0 . 09) .( B)O n l y0 . 1 m g / k g(  )-8-OH-DPAT improved the L-DOPA-induced dyskinesia (LID) score (Fr=14.306; P=0 . 006;
 different
from L-DOPA). (C) Locomotor activity induced by 0.1mg/kg ( )-8-OH-DPATwas no longer different from the OFF situation (grey column).
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 the 6-OHDA-lesioned rat model of L-DOPA-induced
AIMs, the rodent analogue of L-DOPA-induced dyskinesia
(Cenci et al., 1998).
Two groups of 6-OHDA-lesioned rats (n=11 per group)
were subjected to either daily chronic treatment with
L-DOPA at the 6mg/kg dose (plus Benserazide 10mg/kg),
or to the same L-DOPA regimen plus a combination of
5-HT1A and 5-HT1B agonists. The doses of the agonists, ( )-
8-OH-DPAT 0.05mg/kg and CP-94253 1.0mg/kg, were
chosen based on our previous study (Carta et al., 2007)
and was shown to acutely reduce L-DOPA-induced dyskine-
sia by up to 80% in MFB-lesioned rats. As illustrated in
Fig. 2A, the control group, receiving only L-DOPA, showed a
fast onset of AIMs and only two animals were non-dyskinetic
after 2 weeks of treatment (data not shown). In the L-
DOPA+5-HT1 agonists group, in contrast, only three
animals developed some mild dyskinesia, which we defined
here as low responders to the serotonin agonists treatment,
while 8 out of 11 rats were completely free of dyskinesia (see
values of 14th injection of treatment period 1 in Fig. 2C).
Overall, the 5-HT1 agonists-treated group was significantly
protected from dyskinesia compared with the L-DOPA only-
treated group at the end of treatment period 1 (Fig. 2A).
After the first 2 weeks of treatment (treatment period 1),
animals were challenged with a sub-threshold dose of
apomorphine (0.02mg/kg), in absence of any agonist
treatment, and tested for dyskinesia to rule out possible
masking rather than protective effect of the 5-HT1 agonists
on L-DOPA-induced dyskinesia. This experiment revealed a
lower degree of DA receptor sensitization in the animals
previously treated with L-DOPA+5-HT1 agonists compared
to the control group (Fig. 2B). Forty-eight hours after the
apomorphine challenge, treatments were switched so that
the animals previously receiving only L-DOPA now received
L-DOPA plus agonists, and the animals previously receiving
the combined treatment were given L-DOPA alone (treat-
ment period 2). As shown in Fig. 2C, animals now on the
combined treatment showed a significant reduction in the
abnormal movements for the entire experimental period,
with a maximal 90% reduction at the 4th administration.
During the second week, however, we observed gradual
partial loss of efficacy, likely due to the well-known
phenomenon of internalization of the pre-synaptic 5-HT
receptors upon repeated exposure to agonists (El Mansari
et al., 2005; Kuan et al., 2008). Nevertheless, at the end of
treatment period 2, animals appeared still relatively
protected, since the dyskinesia score was significantly
different than the level seen in the same animals at the
end of treatment period 1. Interestingly, the L-DOPA-
treated animals, which were high responders to the agonists
during treatment period 1, appeared to be protected from a
full development of dyskinesia when they received L-DOPA
only during treatment period 2, while the three low
responders in the treatment period 1 developed high
dyskinesia score (Fig. 2C).
After treatment period 2, the animals receiving L-DOPA
plus agonists were treated with L-DOPA only and then given
a 3-week washout period and tested again with L-DOPA and
L-DOPA plus agonists (n=9, two animals that were non-
dyskinetic during period 1 were not included). As shown in
Fig. 2D, this drug-free period was sufficient to allow a
complete recovery from the receptor desensitization induced
by the chronic agonists treatment. The result of this test
suggests that autoreceptor desensitization is a rev-ersible
phenomenon upon discontinuation of the drug treatment.
In agreement with our previous report (Carta et al.,
2007), all 6-OHDA-lesioned animals employed in these
experiments had near-complete depletion of striatal DA
(499% compared to the intact side) as measured by HPLC,
while serotonin tissue levels were unaffected by 6-OHDA
lesions, or administration of the agonists (data not shown).
In order to investigate the impact of the serotonin
agonist treatment on the therapeutic effect of L-DOPA,
we tested motor activity during treatment period 1.
Data expressed as mean SEM (ANOVA followed by Bonferroni, F(5,35)=21.705, P50.0001;
 different from saline,
#different from
L-DOPA, L-DOPA+CP-942531.75, L-DOPA+CP-94253 2.5). Highlight at t=80minoftheimpactupon( D) parkinsonian disability score
(median/range: 0/0^0 for L-DOPA; 0.5/0^1 for 8-OH-DPAT 0.05; 0.5/0^1 for 8-OH-DPAT 0.1; 0/0^0 for CP-942531.75; 0/0^2 for CP-94253
2.5; Fr=7 .57 P=0 . 1 1 )and( E) LID score (median/range: 4/2^4 for L-DOPA; 3.5/2^4 for 8-OH-DPAT 0.05; 1.5/1^2.5 for 8-OH-DPAT 0.1; 3.5/
3^4 for CP-942531.75; 4/1^4 for CP-94253 2.5; Fr=1 4. 082,P=0 . 007 ;
 different from L- D O P A )s h o w i n gt h a to n l y0 . 1 m g / k g(  )-8-OH-DPAT
improved LID. (F) Effect of combination of 5-HT1A (( )-8-OH-DPAT) and 5-HT1B (CP-94253) agonists (8-OH-DPAT 0.05 + CP-942531.75;
8-OH-DP A T0. 1+CP-942531 .75;8-OH-DP A T0.05+CP-942532.5;8-OH-DP A T0. 1+CP-942532.5)togetherwith L-DOPA upon parkin-
sonian disability score (Fr=1 6. 068,P=0.002).Combination at the highest doses (8-OH-DPAT 0.1 + CP-94253 2.5) worsened the Parkinson’s
disease score indicating an anti-L-DOPA effect (P50.05;
 different from L-DOPA). (G) While the lowest doses in combination (8-OH-DPAT
0.05 + CP-942531.75) had no anti-dyskinetic effect, all three others (8-OH-DPAT 0.1 + CP-942531.75; 8-OH-DPAT 0.05+CP-94253 2.5;
8-OH-DPAT 0.1+CP-94253 2.5) significantly improved dyskinesia (Fr=22.256, P=0.0002;
 different from L-DOPA). (H)T h et h r e ec o m b i -
nations 8-OH-DPAT 0.1 + CP-94253 1.75, 8-OH-DPAT 0.05 + CP-94253 2.5 and 8-OH-DPAT 0.1 + CP-94253 2.5 significantly reduced the
number of automated counts. [F(5,35)=1 9 .685 ,P50.0001;
 different from saline,
#different from L-DOPA]. (I) Highlight at t=80min of the
impact upon parkinsonian disability score, further confirmed that only the combination at the highest doses (8-OH-DPAT 0.1+CP-94253
2.5) worsened the Parkinson’s disease score indicating an anti-L-DOPA effect (P50.05;
 different from L-DOPA) (median/range: 0/0 0f o r
L-DOPA; 1/0 1fo r8-O H-D P A T0 . 05+C P -9425 31 .7 5;0 .5 /0 2f o r8- O H - D P A T0 . 0 5+C P - 9 4 2 5 32 . 5 ;1 / 0  1 for 8-OH-DPAT 0.1+CP-94253
1.75; 3/2 3 for 8-OH-DPAT 0.1+CP-94253 2.5; Fr=1 9 .835 ,P=0.0005). (J) In the same way, highlight at t=80m inoft heim pactuponLI D
score (median/range: 4/2^4 for L-DOPA; 3/2^4 for 8-OH-DPAT 0.05 + CP-942531.75; 0.5/0^2 for 8-OH-DPAT 0.05 + CP-94253 2.5; 2/1^2
for 8-OH-DPAT 0.1 + CP-942531.75; 0.5/0^1for 8-OH-DPAT 0.1+CP-94253 2.5; Fr=19.54, P=0.0006) showed that only the two combi-
nations involving the highest dose of the 5-HT1B agonist (8-OH-DPAT 0.05 + CP-94253 2.5; 8-OH-DPAT 0.1 + CP-94253 2.5) improved LID
(P50.05;
 different from L-DOPA).
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 Neither horizontal nor vertical activities were affected
by co-administration of the agonists with L-DOPA com-
pared with L-DOPA only (Fig. 3A and 3B). In addition,
L-DOPA-induced improvement in the forelimb used in the
stepping test was also unaffected by the 5-HT1 agonist
treatment (Fig. 3C). These results are in line with our
previous report (Carta et al., 2007) showing preservation of
the therapeutic effect of L-DOPA in the cylinder test of
Fig. 2 Chronic effectof 5-HT1A +5-HT 1B agonists on L-DOPA-induceddyskinesia in 6-OHDA-lesionedrats.Co-administration of
5-HT 1A +5-HT 1B agonists with L-DOPA resulted in a significant inhibition of the development of dyskinesia (reported as the sum of limb, axial
andorolingualmovements) at the endof the treatmentperiod1 [(A); mean SEMatthe14thadministration: 557 84versus96 52 in the L-
DOPAonly and L-DOPA+5-HTagonists-treatedgroups, respectively;P=0.001in the Mann^Whitney test; n=1 1perg roup] .Th reean imals,
however,appearedtobelowresponders to theagonists treatmentanddevelopedsomedegree ofdyskinesia,while the othereightratswere
completely free of dyskinesia (seevalues of the14thinjectionin the treatmentperiod1in (C).The apomorphine (0.02mg/kg, s.c.)-induced
dyskinesia test revealed a significant lower sensitization state of the DA receptors in the L-DOPA+5-HT1A +5-HT 1B agonists-treatedgroup
[(B); mean SEM: 203 31 versus 66  20 in the L-DOPA only and L-DOPA+5-HT1A +5-HT 1B agonists-treatedgroups, respectively;P=0 . 02
in the Mann^Whitney test; n=11pergroup).Treatmentswere then switchedduring treatmentperiod 2 (C).Theresults showeda significant
reduction of dyskinesia in the L-DOPA+5-HT1A +5-HT 1B agonists-treatedgroup comparedwith thelast score at the end of the treatment
period1, whichwasmaximal (90% reduction) at the 4th administration (mean SEM: 56  29 versus 557 84inthe L-DOPA +5-HT1A +
5-HT 1B agonists at the 4th administration of treatmentperiod 2 and L-DOPA only at the14th administration of treatmentperiod1, respec-
tively; P=0.009 in the Mann^Whitney test; n=1 1forL-DOPA + 5-HT1A +5-HT 1B agonistsgroup) and stillpresent at thelast treatment
(mean  SEM: 308  72 versus 557 84inthe L-DOPA+5-HT1A +5-HT 1B agonists at the14th administration of treatmentperiod 2 and
L-DOPA only at the14th administration of treatmentperiod1, respectively;P=0.039 in the Mann^Whitney test). In addition, only the three
lowresponders to the agonists of the treatmentperiod1developedhigh dyskinetic score, while a significantprotectionwas observedin the
L-DOPA-treatedgrouppreviouslyresponsive to the agonists treatmentcompared to the L-DOPA-treatedgroup at the end of the treatment
period1 [(C); mean SEM:109 33 versus 557 84inthe L-DOPAonlyat the14th administration of treatmentperiod 2 and L-DOPA onlyin
the14th administration of treatmentperiod1, respectively;P=0 . 008int heMann^Wh itne ytest;n=8forhi ghresponders,n=3forlow
responders). After a 3-week washout 5-HT1agonists treatmentregained a full efficacy [(D); mean SEM: 377  69 versus111  42 under
tolerance and after wash-out, respectively;P=0 . 007int heMann^Wh it ne ytest;n=9) .
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 partial 6-OHDA-lesioned rats after co-administration with
the same 5-HT agonists.
Effect of the chronic administration of the
5-HT 1A +5- H T 1B agonists on the number
of FosB-positive cells in striatum
Swings in striatal DA release and consequent pulsatile
stimulation of striatal DA receptors generated by inter-
mittent L-DOPA administration have been suggested to be
responsible for a cascade of events in the post-synaptic
striatal neurons, which eventually result in changes in gene
expression and appearance of dyskinesia. Thus, induction of
FosB, has been proposed as a marker of the cellular changes
underlying the side effects of L-DOPA (Andersson et al.,
1999). To investigate whether co-treatment with the
serotonin receptor agonists may affect L-DOPA-induced
up-regulation of this marker, one additional group of
6-OHDA-lesioned rats was included and subjected to the
same treatment as above. After treatment period 1, animals
were sacrificed, brains removed and sectioned for FosB
immunostaining. A significant correlation between AIM
score and number of FosB-positive cells was found
(coefficient of correlation, r=0.72 and 0.76 for the total
striatum and the lateral part, respectively). As shown in
Fig. 4, co-administration of 5-HT1A+5-HT1B agonists with
L-DOPA resulted in a significant reduction of FosB-positive
cells compared with the L-DOPA-treated dyskinetic animals,
particularly in the lateral part of the striatum, which has
been suggested to play an important role in the induction
of dyskinesia (Cenci et al., 1998; Andersson et al., 1999).
Interestingly, all animals in the dyskinetic L-DOPA-treated
group had higher numbers of FosB-positive cells than any
of the ones in the L-DOPA+5-HT1 agonist-treated group,
with an average reduction of 48% and 61% when con-
sidering the entire striatum or the lateral part, respectively.
As expected, a sub-group of L-DOPA-treated rats did not
develop dyskinesia. In these animals, the number of FosB-
positive cells was similar to that found in the drug naı ¨ve
group, except in one case, where the number of FosB-
positive cells was similar to the dyskinetic animals. This
animal, however, in contrast to the other non-dyskinetic
animals, had a high-rotational response to the administra-
tion of L-DOPA, which may explain FosB induction. It is
worth to note that FosB-positive nuclei in the dyskinetic
group appeared also to be more intensely stained than in
the agonist-treated group, suggesting a higher amount of
FosB expression per cell (data not shown).
Alteration in NMDA receptor subunits
composition
Physiological stimulation of the DA receptors is known to
be important for regulation of trafficking of striatal NMDA
Fig. 3 Effect of the 5-HT1A/1B agonists on the therapeutic effect of L-DOPA in 6-OHDA-lesioned rats.Co-administration of the
agonists with L-DOPA did not reduce the ability of L-DOPA to improve horizontal (mean SEM: 19 887 5524,14576 3255, 7967 2150
and 2500 313 for L-DOPA+5-HT1A +5-HT 1B agonists, L-DOPA only, agonists only and saline, respectively; P50.05 for
L-DOPA+5-HT1A +5-HT 1B agonists versus saline, L-DOPA only versus saline and 5-HT1A +5-HT 1B agonists only versus saline in the
Kruskal^Wallis followed by Mann^Whitney test;
 different from saline) and vertical activity (mean SEM: 586 195, 351  94,121 33
and 52 12 for L-DOPA+5-HT1A +5-HT 1B agonists, L-DOPA only, 5-HT1A +5-HT 1B agonists only and saline, respectively; P50.05 for
L-DOPA+5-HT1A +5-HT 1B agonists versus saline, L-DOPA only versus saline, L-DOPA only versus 5-HT1A +5-HT 1B agonists only in the
Kruskal^Wallis followed by Mann^Whitney test;
 different from saline,
#=different from agonists). In addition, performance of the ani-
mals in the stepping test was tested after L-DOPA administered with or without the 5-HT1A +5-HT 1B agonists (C).The results show that
co-administration of the 5-HT1A +5-HT 1B agonists did not reduce the ability of L-DOPA to improve the number of steps of theparkinsonian
forelimb (mean SEM: 2.3  0.8 versus 4.8   0.7 in baseline condition and 60min after L-DOPA, respectively in the na|«ve group, P=0 . 0 1 7in
the Mann^Whitney test; 0.7 0.2 versus 5.7  1.0 in baseline condition and 60min after L-DOPA, respectively in the L-DOPA+5-HT1A +5-
HT1B agonists group, P50.001 in the Mann^Whitney test;
 different from baseline).
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 receptors (Dunah and Standaert, 2001). Accordingly, DA
denervation and un-physiological, pulsatile stimulation of
striatal DA receptors, induced by intermittent L-DOPA
administration, have been reported to alter synaptic levels
of NMDA receptor subunits and associated PSD proteins
(Fiorentini et al., 2006; Gardoni et al., 2006). To investigate
whether modulation of pre-synaptic DA release by means of
5-HT1 agonists may affect synaptic levels of NMDA
receptor subunits and PSD proteins, an additional group
of animals was subjected to the treatment period 1 and
western blot analysis was carried out in different cellular
fractions. Consistent with the earlier studies, we observed in
the 6-OHDA-lesioned rats a down-regulation of the NR2B
subunit content in the TIF, which is enriched in PSD
proteins, in absence of a parallel alteration of the NR2A
subunit in the same samples (Fig. 5A and B). Induction of
dyskinesia by chronic, daily treatment with L-DOPA was
accompanied by a significant up-regulation of the NR2B
subunit in the same cellular compartment, and co-
administration with the 5-HT1 agonists resulted in a
further significant up-regulation of these subunits in the
non-dyskinetic (agonist-treated) rats compared with all
other experimental groups. In line with previous studies
(Fiorentini et al., 2006; Gardoni et al., 2006), this alteration
is interpreted to reflect a redistribution of the subunits
between different cellular compartments (synaptic versus
extra-synaptic), since the total tissue content was not
affected (data not shown). The content of the NR2A
subunit in the TIF, in contrast, was similar in all
experimental groups (Fig. 5A). Furthermore, no modifica-
tion of PSD-95 and SAP97 members of PSD-MAGUKs
proteins in the TIF was induced by any of the treatments
(Fig. 5A).
Discussion
The present results show that 5-HT1A and 5-HT1B agonists
have a synergistic effect in suppressing L-DOPA-induced
dyskinesia in the MPTP-treated macaque. Sub-threshold
doses of the drugs, which individually produced very
little, unsignificant effects, were able to reduce dyskinesia
severity by up to 80% when administered in combination,
without affecting the anti-parkinsonian properties of
L-DOPA. In addition, we show that daily co-administration
of the 5-HT1A and 5-HT1B agonists can prevent develop-
ment of L-DOPA-induced abnormal involuntary move-
ments and associated striatal alterations, such as striatal
FosB induction, without reducing the therapeutic
effect of L-DOPA in the rat Parkinson’s disease model.
These data extend our previous observations pointing to
the serotonin system as a critical element in L-DOPA-
induced dyskinesia (Carta et al., 2007) and highlight the
potential clinical application of 5-HT1A and 5-HT1B for the
management of L-DOPA-induced dyskinesia in Parkinson’s
disease patients.
Fig. 4 Effect of the chronic administration of the 5-HT1A +5-HT 1B agonists on the number of FosB-positive cells in striatum. Significant
correlation between AIM score and number of FosB-positive cells was found in animals exposed to the treatment period1 (coefficient of
correlation r was 0.72 and 0.76 for the total striatum and the lateral part, respectively; two brain sections were considered and all striatal
FosB-positive cells were counted).Co-administration of the 5-HT1A +5-HT 1B agonists with L-DOPA (n=9) resulted in a significant reduc-
tion of FosB-positive cells compared with the L-DOPA-treated dyskinetic animals (n=9), when considering both the entire
striatum (mean SEM: 5258 569,1783 1001, 2749  289 and1528 517 in the dyskinetic L-DOPA, non-dyskinetic L-DOPA,
L-DOPA+5-HT1A +5-HT 1B agonists treated and na|«ve groups, respectively; ANOVA followed by Bonferroni test: F(3,19)=8. 992;P50.001
for dyskenetic L-DOPA versus na|«ve, P=0 . 003fordyskinet icL-DOPA versus non-dyskinetic L-DOPA, P=0.01 for dyskinetic L-DOPA versus
L-DOPA+5-HT1A +5-HT 1B agonists) and the lateral part (mean SEM: 2048 157, 712  458, 790 99 and 330 112 in the dyskinetic
L-DOPA, non-dyskinetic L-DOPA, L-DOPA+5-HT1A +5-HT 1B agonists treated and na|«ve groups, respectively; ANOVA followed by
Bonferroni test: F(3,19)= 13 418; P50.001for dyskinetic L-DOPAversus na|«ve, P=0 . 002fordyskinet icL-DOPAversus non-dyskinetic L-DOPA,
P50.001 for dyskinetic L-DOPA versus L-DOPA+5-HT1A +5-HT 1B agonists) (
#different from non-dyskinetic L-DOPA, L-DOPA+5-
HT1A +5-HT 1B agonists and na|«ve).
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 Effect of 5HT1A/1B treatment in
6-O H D A-lesionedrats
Physiological regulation of extracellular DA levels is
normally maintained by the presence of the D2 auto-
receptor and DA transporter on the pre-synaptic DA
terminals. These elements represent a feedback controlled
mechanism able to fine tune the level of DA in the synaptic
cleft (Venton et al., 2003; Cragg and Rice, 2004). We have
recently suggested (Carta et al., 2007) that lack of this
feedback control mechanism of DA release from the
serotonin terminals is responsible for the high swings in
synaptic DA after L-DOPA administration, which have been
associated with un-physiological, pulsatile stimulation of
the DA receptors in the striatal neurons and appearance of
dyskinesia (Chase, 1998; de la Fuente-Fernandez et al.,
2004a, b). Indeed, in the present study, in agreement with
the suggested mechanism of action (i.e. modulation of pre-
synaptic release of DA from the serotonin terminals)
administration of 5-HT1 agonists resulted in a significant
protection from development of dyskinesia and reduced
up-regulation of FosB in striatal target neurons (Fig. 2A
and 4), a well-established marker of L-DOPA-induced DA
receptor sensitization (Andersson et al., 1999). In addition,
physiological stimulation of striatal DA receptor is required
for normal trafficking of NMDA receptor subunits in
striatal target neurons (Dunah and Standaert, 2001).
Accordingly, DA denervation affects synaptic level of NR2
subunits and their interaction with PSD proteins (Gardoni
et al., 2006). In line with previous observations (Gardoni
et al., 2006), we found here an up-regulation of the NR2B
subunits in the triton-insoluble fraction in the non-
dyskinetic, agonists-treated rats (Fig. 5). In contrast to the
previous report, however, a significant increase of the NR2B
subunit was also found in the L-DOPA-treated dyskinetic
rats compared with lesioned, saline-treated animals.
Different experimental conditions, such as the L-DOPA
dose (6mg/kg versus 10mg/kg), the gender employed in
these studies (female versus male) and different lesion
protocols (MFB versus nigral 6-OHDA injections) might
account for these discrepancies. Nevertheless, up-regulation
of the NR2B subunit at the post-synaptic membrane
compared with the intact control side of the brain appears
to be a characteristic feature of the non-dyskinetic animals.
Given the suggested role of the striatal NMDA receptors
in the induction and maintenance of dyskinesias, re-
distribution of the striatal NMDA receptor NR2B subunits
between synaptic and extra-synaptic compartments might
play a role in the prevention of dyskinesia upon 5-HT1
agonist administration. The results highlight the interplay
between striatal pre- and post-synaptic alterations in
L-DOPA-induced dyskinesia and confirm previous reports
pointing to the NR2B subunits as a critical receptor in
dyskinesia (Hadj Tahar et al., 2004; Gardoni et al., 2006).
Fig. 5 Effect of the chronic administration of the 5-HT1A +5-HT 1B agonists on the NMDA receptor subunits composition. Animals were
subjected to the treatment period1and sacrificed for quantification of the NMDA receptor subunits NR2B and NR2A, as well as for
quantification of the PSD proteins PSD95 and SAP97 . 6-OHDA lesions induced down-regulation of the NR2B subunit content in theTIF.
Chronic daily treatment with L-DOPAwas accompanied by a significant up-regulation of the NR2B subunit in the same cellular compart-
ment. In addition, serotonin agonists (with L-DOPA) treatment resulted in a further significant up-regulation of these subunits in the non-
dyskinetic (agonist-treated) rats compared with all other experimental groups (mean SEM, percentage respect to intact control sides:
67  18, 74   6, 98 20 and140 9 for 6-OHDA/na|«ve (n= 5), 6-OHDA/5-HT1A +5-HT 1B agonists (n= 6), 6-OHDA/L-DOPA (n=6)and
6-OHDA/L-DOPA+5-HT1A +5-HT 1B agonists (n=6), respectively; ANOVA followed by Bonferroni: P=0.017 for 6-OHDAversus control,
P= 0.014 for 6-OHDA/5-HT1A +5-HT 1B agonists versus control, P=0.009 for L-DOPA+5-HT1A +5-HT 1B agonists versus L-DOPA, P=0 . 029
for L-DOPA versus 6-OHDA and P50.001 for L-DOPA+5-HT1A +5-HT 1B agonists versus 6-OHDA).This alteration seems to reflect a
redistribution of the NR2B receptor between the cellular compartments since no change in the total homogenate was detected
(mean  SEM, percentage respect to intact control sides: 94 38,104 20, 92  23 and 88 16 for 6-OHDA/na|«ve, 6-OHDA/
5-HT 1A +5-HT 1B agonists, 6-OHDA/L-DOPA and 6-OHDA/L-DOPA+5-HT1A +5-HT 1B agonists, respectively). No modification of NR2A,
PSD95 and SAP97 in theTIF was induced by any experimental treatment performed, suggesting that alteration was specific for NR2B.
(
 different from control;
#different from L-DOPA;
‰different from 6-OHDA/saline).
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 It is worth noting that chronic administration of the
5-HT1A and 5-HT1B agonists from the very first dose of
L-DOPA appears to provide a long-term protection against
development of dyskinesia. In fact, animals treated with the
agonists during the treatment period 1, and highly
responsive to the treatment, appeared to be resistant to
the induction of dyskinesia when they received L-DOPA
during the treatment period 2 (Fig. 2A and C). Further
investigations would be required to investigate the mole-
cular basis of this event.
Recently, Eskow et al. (2007) have found protection from
development of dyskinesia in the same animal model by
chronic administration of the partial 5-HT1A agonist
buspirone. 5-HT1A agonists, however, are known to act
not only on pre-synaptic serotonin receptors, but also on
post-synaptic receptors located in other brain areas, such as
the pre-frontal cortex (Yamada et al., 1988; Ceci et al.,
1994; Knobelman et al., 2000). Activation of these receptors
are known to dampen the activity of the glutamategic
neurons projecting to the striatum. Reduced glutamatergic
activity is thus an alternative mechanism that may account
for the anti-dyskinetic effect found by these authors
(Antonelli et al., 2005; Mignon and Wolf, 2005; Carta
et al., 2007). Activation of post-synaptic 5-HT1B receptors
has also been suggested to produce anti-dyskinetic effect by
dampening release of GABA in striatum and substantia
nigra pars reticulata (Zhang et al., 2008).
Activation of the post-synaptic 5-HT1 receptors has been
linked to induction of serotonin syndrome both in rats and
non-human primates, an effect that may seriously com-
promise motor function (Goodwin et al., 1986; Smith and
Peroutka, 1986; Yamada et al., 1988). In our experimental
conditions, doses of the agonists were chosen, based on our
previous work (Carta et al., 2007), in order to target the
pre-synaptic serotonin receptors. Indeed, the 5-HT1 ago-
nists were unable, at the present doses, to produce
reduction of apomorphine-induced dyskinesia in a group
of MFB-lesioned dyskinetic rats (data not shown). Thus, at
low doses, the efficacy of the 5-HT1 agonists in counter-
acting L-DOPA-induced dyskinesia is suggested to be due to
the dampening effect on the release of DA from the
serotonin neurons rather than to reduced glutamatergic
input into the striatum (Carta et al., 2007). Importantly,
administration of the agonists did not appear to reduce the
therapeutic effect of L-DOPA, as assessed in tests of general
motor activity and from the performance in the stepping
test (Fig. 3).
Effect of 5HT1A/1B treatment in
MPTP-treated macaques
MPTP-treated monkeys provide the best available animal
model of Parkinson’s disease, which shares several features
with the human disease. In the present study, we took
advantage of this model in order to investigate the validity
of the serotonin agonist approach in primates. Interestingly,
we report here a similar synergistic effect between the two
agonists as the one previously shown in the rat model.
Thus, combining doses, which individually produced
no effect [( )-8-OH-DPAT 0.05mg/kg and CP-94253
2.5mg/kg)], we could observe a marked decrease in the
abnormal movements (by about 80% reduction in the
AUC) (Fig. 1G). Importantly, this effect was obtained
without any significant worsening of the therapeutic effect
of L-DOPA (Fig. 1F). Combination of the same dose of
CP-94253 (2.5mg/kg) with a higher dose of ( )-8-OH-
DPAT (0.1mg/kg) produced a near-complete suppression
of L-DOPA-induced dyskinesia (about 95% reduction in
the AUC). However, this combination produced 28%
reduction in the therapeutic efficacy of L-DOPA, although
a significant therapeutic value of L-DOPA was still retained
relative to the baseline impairment (Fig. 1F).
Previous primate studies have given conflicting results on
the possibility of reducing the release from the serotonin
neurons by 5-HT1A or 5-HT1B receptor agonists without
interfering with the efficacy of L-DOPA medication. Indeed,
a partial reduction of L-DOPA-induced dyskinesia in
MPTP-lesioned marmosets treated with (+)-8-OH-DPAT
has been reported, but this effect was accompanied by
worsening of parkinsonism (Iravani et al., 2006). Others,
however, have shown that the partial 5-HT1A agonist
Sarizotan can reduce L-DOPA-induced dyskinesia in
MPTP-treated macaques without significantly deteriorating
the efficacy of L-DOPA (Bibbiani et al., 2001). The different
species employed and/or differences in the magnitude of
MPTP-induced DA depletion might account for the
discrepancies between these studies. Indeed, preservation
of a residual DA innervation could have profound
consequences on the therapeutic efficacy of L-DOPA when
DA release from serotonin neurons is silenced. Spared DA
terminals are likely to serve as a buffer for L-DOPA-derived
DA after intermittent L-DOPA administration, and mediate
a physiological, feedback-regulated release of DA.
The decreased anti-parkinsonian effect of L-DOPA
reported by Iravani and colleagues after (+)-8-OH-DPAT
treatment could, at least in part, also be due to the high
dose of 5-HT1A agonist needed to obtain a significant anti-
dyskinetic effect, when given alone. Indeed, these authors
observed signs of serotonin syndrome after administration
of (+)-8-OH-DPAT in MPTP-lesioned marmosets, which
may have contributed to the appearance of hypokinesia and
dystonia in their animals as we previously observed in
MPTP-treated animals when using high doses of compar-
able drugs (Bezard et al., 2006). In the same study,
the authors observed a similar reduction in the anti-
parkinsonian effect of the D2/D3 direct agonist pramipexole
after co-administration with (+)-8-OH-DPAT, an observa-
tion which may suggest a post-synaptic-related side effect
due to the high dose of the drug. Different properties of the
drugs employed might also account for the discrepancies
between our results and those reported by Iravani and
colleagues. Indeed, (+)-8-OH-DPAT was notably less
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 potent than ( )-8-OH-DPAT in counteracting dyskinesia
in our 6-OHDA-lesioned rats (data not shown).
A 5-HT1B receptor agonist has also been tested
individually in MPTP-treated dyskinetic marmosets
(Jackson et al., 2004). However, the anti-dyskinetic effect
of the compound employed resulted in a diminished
therapeutic effect of L-DOPA. We did not observe any
detrimental effect of CP-94253 individually at the doses
used here in the MPTP-treated macaques, although these
doses neither resulted in anti-dyskinetic effect. Higher doses
may produce different effects. However, this goes beyond
the purpose of the study, since the sub-threshold dose
already produced a near-complete suppression of dyskinesia
when combined with ( )-8-OH-DPAT.
In line with the present results, elevation of the
serotonergic tone induced by the psychotropic drug
MDMA has been also found to produce reduction of the
pro-dyskinetic effect of L-DOPA in MPTP-treated marmo-
sets by mechanism partly involving 5-HT1A/1B receptors
(Iravani et al., 2003).
Clinical implications
Pharmacological blockade of serotonin neuron activity
by 5-HT1A and 5-HT1B receptor agonists, particularly in
combination, might have potential clinical application in
Parkinson’s disease patients. Indeed, the 5-HT1A partial
agonist Sarizotan has been recently tested for its anti-
dyskinetic properties, not only in MPTP-treated monkeys,
but also in Parkinson’s disease patients (Olanow et al.,
2004; Goetz et al., 2007). However, despite promising
results in the earlier clinical investigations, a large phase III
clinical trial was recently terminated for lack of efficacy.
Although a detailed report of the phase III trial has not
been published yet, there are several factors that may
account for the failure to obtain any significant anti-
dyskinetic effect in this study. First, the dose of drug chosen
for this trial might have been too low to provide the
necessary blockade of DA release from the serotonin
terminals. Second, Sarizotan has also some antagonistic
properties on the DA receptors, which might explain in
part the side effects observed in the early trial, particularly
the worsening of the parkinsonism (Olanow et al., 2004). In
light of the preclinical results discussed above, and
assuming that the serotonin terminals play a similar role
in mediating L-DOPA-derived DA release in humans, it is
also possible that targeting the 5-HT1A receptors alone is
not sufficient to provide a significant control of the
excessive swings in DA release and therefore of dyskinesias.
According to our rodent and primate data, simultaneous
activation of the 5-HT1A and 5-HT1B receptors should
result in a more potent effect and in a better control of the
motor side effects of L-DOPA medication, at doses acting
mainly on the pre-synaptic receptors.
It is worth noting that the MPTP-treated primate model
resembles the end stage of the disease in humans. In such a
situation, the therapeutic effect of L-DOPA might partly
depend on DA released from the serotonin terminals.
The partial reduction of the efficacy of L-DOPA observed
with the higher doses of the serotonin agonist in our
monkey experiment seems to support this view. Less
advanced Parkinson’s disease patients are likely to retain
some residual DA innervation, which can mediate
L-DOPA-derived DA production and sustain the therapeutic
effect of the drug. In such cases, even a complete blockade of
DA release from the serotonin terminals should not have any
major impact on the therapeutic effect of L-DOPA. If this is
correct, careful selection of patients would be necessary in
order to ensure maximal benefit from serotonin agonist
treatment. Our rodent data showing prevention of dyskinesia
upon chronic treatment with the serotonin agonists also
speaks in favour of an early intervention as a way to avoid
the development of troublesome dyskinesia and maintain
intact therapeutic value of L-DOPA. Finally, as 5HT1A
agonists have shown neuroprotective efficacy in clinically
relevant experimental designs using various animal models of
Parkinson’s disease including the MPTP-treated macaque
(Bezard et al., 2006), an early introduction of such drugs
could potentially slow down the neurodegenerative process,
further supporting the case of this class of drugs.
Possible induction of tolerance upon repeated administra-
tion of the serotonin agonists is a concern for this approach.
Indeed, desensitization of pre-synaptic 5-HT1A receptor is a
well-known phenomenon linked to chronic administration of
serotonin reuptake inhibitors, and explains the delayed
therapeutic efficacy of these drugs (El Mansari et al., 2005;
Kuan et al., 2008). Our data indicate that development of
desensitization may reduce the anti-dyskinetic effect of the
combined agonist treatment over time. In a clinical setting,
this suggests that treatment sessions followed by wash-out
periods may be needed to avoid this effect.
In conclusion, the results of the present study highlight
the critical role of the serotonin system in the induction of
L-DOPA-induced dyskinesia in the rat, as well as monkey
Parkinson’s disease model and the ability of serotonin
5-HT1 receptor agonists to counteract this side effect. The
demonstration of a synergistic effect between 5-HT1A and
5-HT1B receptor agonists in primates may have interesting
clinical implication for the treatment of L-DOPA-induced
dyskinesia in Parkinson’s disease patients, where targeting
of the 5-HT1A alone has not produced the expected efficacy.
Acknowledgements
We thank Ulla Jarl, Anneli Josefsson, Bengt Mattsson, Li
Hao, Baishen Ren, Elisa Zianni and Li Jun for expert
technical assistance.
Funding
Swedish Research Council (04X-3874 to A.B.);
Parkinsonfonden; Parkinson’s Disease Foundation (to
M.C.); Michael J Fox Foundation (to M.C.).
5-HT 1A and 5-HT1B agonists for dyskinesia Brain (2008) Page13 of15
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
6
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 References
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and
motor fluctuations as estimated from the cumulative literature. Mov
Disord 2001; 16: 448–58.
Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally
linked with l-DOPA-induced abnormal involuntary movements and the
associated upregulation of striatal prodynorphin mRNA in a rat model
of Parkinson’s disease. Neurobiol Dis 1999; 6: 461–74.
Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA,
Tanganelli S, et al. Effects of sarizotan on the corticostriatal glutamate
pathways. Synapse 2005; 58: 193–9.
Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I.
Immunohistochemical evidence that central serotonin neurons produce
dopamine from exogenous L-DOPA in the rat, with reference to the
involvement of aromatic L-amino acid decarboxylase. Brain Res 1994;
667: 295–9.
Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, et al.
Increased D1 dopamine receptor signaling in levodopa-induced
dyskinesia. Ann Neurol 2005; 57: 17–26.
Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced
dyskinesia: potential for new therapies. Nat Rev Neurosci 2001a; 2: 577–88.
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D,
et al. Relationship between the appearance of symptoms and the level of
nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-lesioned macaque model of Parkinson’s disease.
J Neurosci 2001b; 21: 6853–61.
Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, et al.
Attenuation of levodopa-induced dyskinesia by normalizing dopamine
D3 receptor function. Nat Med 2003; 9: 762–7.
Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R. 5-HT1A receptor
agonist-mediated protection from MPTP toxicity in mouse and
macaque models of Parkinson’s disease. Neurobiol Dis 2006; 23: 77–86.
Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor
complications in rodent and primate parkinsonian models. Neurology
2001; 57: 1829–34.
Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. Serotonin neuron
transplants exacerbate L-DOPA-induced dyskinesias in a rat model of
Parkinson’s disease. J Neurosci 2007; 27: 8011–22.
Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, et al.
Reversal of dyskinesias in an animal model of Parkinson’ disease by
continuous L-DOPA delivery using rAAV vectors. Brain 2005; 128:
559–69.
Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT
terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian
rats. Brain 2007; 130: 1819–33.
Carta M, Fadda F, Stancampiano R. Tryptophan-deficient diet increases
the neurochemical and behavioral response to amphetamine. Brain Res
2006; 1094: 86–91.
Ceci A, Baschirotto A, Borsini F. The inhibitory effect of 8-OH-DPAT on
the firing activity of dorsal raphe serotoninergic neurons in rats is
attenuated by lesion of the frontal cortex. Neuropharmacology 1994; 33:
709–13.
Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the
rat is associated with striatal overexpression of prodynorphin-
and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998; 10:
2694–706.
Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-
induced dyskinesia. J Neurochem 2006; 99: 381–92.
Chase TN. Levodopa therapy: consequences of the nonphysiologic
replacement of dopamine. Neurology 1998; 50: S17–25.
Cragg SJ, Rice ME. DAncing past the DAT at a DA synapse. Trends
Neurosci 2004; 27: 270–7.
de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ.
Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a
probabilistic model. Brain 2004a; 127: 888–99.
de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB,
et al. Levodopa-induced changes in synaptic dopamine levels increase
with progression of Parkinson’s disease: implications for dyskinesias.
Brain 2004b; 127: 2747–54.
Dunah AW, Standaert DG. Dopamine D1 receptor-dependent trafficking
of striatal NMDA glutamate receptors to the postsynaptic membrane.
J Neurosci 2001; 21: 5546–58.
El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of
acute and long-term administration of escitalopram and citalopram on
serotonin neurotransmission: an in vivo electrophysiological study in rat
brain. Neuropsychopharmacology 2005; 30: 1269–77.
Eskow KL, Gupta V, Alam S, Park JY, Bishop C. The partial 5-HT(1A)
agonist buspirone reduces the expression and development of l-DOPA-
induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol
Biochem Behav 2007; 87: 306–14.
Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, et al.
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor
complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol
2006; 69: 805–12.
Gardoni F, Schrama LH, Kamal A, Gispen WH, Cattabeni F, Di Luca M.
Hippocampal synaptic plasticity involves competition between Ca2+/
calmodulin-dependent protein kinase II and postsynaptic density 95 for
binding to the NR2A subunit of the NMDA receptor. J Neurosci 2001;
21: 1501–9.
Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, et al.
A critical interaction between NR2B and MAGUK in L-DOPA induced
dyskinesia. J Neurosci 2006; 26: 2914–22.
Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, et al.
Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-
blind placebo-controlled trial. Mov Disord 2007; 22: 179–86.
Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, et al. RGS9-2
negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia
in experimental Parkinson’s disease. J Neurosci 2007; 27: 14338–48.
Goodwin GM, De Souza RJ, Wood AJ, Green AR. The enhancement by
lithium of the 5-HT1A mediated serotonin syndrome produced by
8-OH-DPAT in the rat: evidence for a post-synaptic mechanism.
Psychopharmacology 1986; 90: 488–93.
Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, et al.
Levodopa-induced dyskinesia in MPTP-treated macaques is not
dependent on the extent and pattern of nigrostrial lesioning. Eur J
Neurosci 2005a; 22: 283–7.
Guigoni C, Li Q, Aubert I, Dovero S, Bioulac BH, Bloch B, et al. Involvement
of sensorimotor, limbic, and associative basal ganglia domains in
L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 2005b; 25:
2102–7.
Hadj Tahar A, Gregoire L, Darre A, Belanger N, Meltzer L, Bedard PJ.
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias
in drug-naive parkinsonian monkeys. Neurobiol Dis 2004; 15: 171–6.
Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat
striatum after L-dopa administration. J Pharmacol Exp Ther 1981; 217:
189–97.
Hollister AS, Breese GR, Mueller RA. Role of monoamine neural systems
in L-dihydroxyphenylalanine-stimulated activity. J Pharmacol Exp Ther
1979; 208: 37–43.
Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE. Comparison of eight
clinical rating scales used for the assessment of MPTP-induced
parkinsonism in the Macaque monkey. J Neurosci Methods 2000; 96:
71–6.
Iravani MM, Jackson MJ, Kuoppama ¨ki M, Smith MA, Jenner P.
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia
expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated primates. J Neurosci 2003; 23: 9107–15.
Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. In MPTP
treated primates, the selective 5-HT1a agonist (R)-(+)-8-hydroxy-DPAT
inhibits levodopa-induced dyskinesia but only with increased motor
disability. J Pharmacol Exp Ther 2006; 319: 1225–34.
Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P.
Effect of 5-HT1B/D receptor agonist and antagonist administration on
Page14 of15 Brain (2008) A. Mun ‹ oz et al.
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
6
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 motor function in haloperidol and MPTP-treated common marmosets.
Pharmacol Biochem Behav 2004; 79: 391–400.
Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M.
Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an
increase in extracellular dopamine derived from exogenously adminis-
tered L-DOPA in the striatum with nigrostriatal denervation.
J Neurochem 2001; 76: 1346–53.
Kirik D, Winkler C, Bjo ¨rklund A. Growth and functional efficacy of
intrastriatal nigral transplants depend on the extent of nigrostriatal
degeneration. J Neurosci 2001; 21: 2889–96.
Knobelman DA, Kung HF, Lucki I. Regulation of extracellular con-
centrations of 5-hydroxytryptamine (5-HT) in mouse striatum by
5-HT(1A) and 5-HT(1B) receptors. J Pharmacol Exp Ther 2000; 292:
1111–17.
Kuan WL, Zhao JW, Barker RA. The role of anxiety in the develop-
ment of levodopa-induced dyskinesias in an animal model of
Parkinson’s disease, and the effect of chronic treatment with the
selective serotonin reuptake inhibitor citalopram. Psychopharmacology
2008; 197: 279–93.
Lee CS, Cenci MA, Schulzer M, Bjorklund A. Embryonic ventral
mesencephalic grafts improve levodopa-induced dyskinesia in a rat
model of Parkinson’s disease. Brain 2000; 123: 1365–79.
Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA.
Pharmacological validation of behavioural measures of akinesia and
dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 2002;
15: 120–32.
Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert
exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980; 8:
558–63.
Mignon LJ, Wolf WA. 8-hydroxy-2-(di-n-propylamino)tetralin reduces
striatal glutamate in an animal model of Parkinson’s disease.
Neuroreport 2005; 16: 699–703.
Ng KY, Chase TN, Colburn RW, Kopin IJ. L-Dopa-induced release of
cerebral monoamines. Science 1970; 170: 76–7.
Ng KY, Colburn RW, Kopin IJ. Effects of L-dopa on efflux of cerebral
monoamines from synaptosomes. Nature 1971; 230: 331–2.
Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in
Parkinson’s disease. Trends Neurosci 2000; 23: S2–7.
Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, et al.
Multicenter, open-label, trial of sarizotan in Parkinson disease patients
with levodopa-induced dyskinesias (the SPLENDID Study). Clin
Neuropharmacol 2004; 27: 58–62.
Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego:
Academic Press; 1998.
Peter D, Liu Y, de Giorgio R, Brecha N, Edwards RH. Differential
expression of two vesicular monoamine transporters. J Neurosci 1995;
15: 6179–88.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE.
A five-year study of the incidence of dyskinesia in patients with
early Parkinson’s disease who were treated with ropinirole or levodopa.
056 Study Group. N Engl J Med 2000; 342: 1484–91.
Schallert T, Norton D, Jones TA. A clinically relevant rat model of
Parkinsonian akinesia. J Neural Transpl Plast 1992; 3: 332–3.
Smith LM, Peroutka SJ. Differential effects of 5-hydroxytryptamine1a
selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem
Behav 1986; 24: 1513–19.
Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M.
Role of serotonergic neurons in L-DOPA-derived extracellular dopa-
mine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999; 10:
631–4.
Taylor JR, Elsworth JD, Roth RH, Sladek JR, Redmond DE. Behavioral
effects of MPTP administration in the Vervet monkey, a primate model
of Parkinson’s disease. In: Woodruff ML, Nonneman A, editors. Toxin-
induced models of neurological disorders. New York: Plenum Press;
1994: p. 139–51.
Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M.
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization
to L-DOPA in a rodent model of Parkinson’s disease. Neurosci Res
2005; 52: 185–94.
Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM.
Real-time decoding of dopamine concentration changes in the caudate-
putamen during tonic and phasic firing. J Neurochem 2003; 87:
1284–95.
Yamada J, Sugimoto Y, Horisaka K. The behavioural effects of 8-hydroxy-
2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur J Pharmacol
1988; 154: 299–304.
Zhang X, Andren PE, Greengard P, Svenningsson P. Evidence for a role of
the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment
of an animal model of Parkinsonism. Proc Natl Acad Sci USA 2008; 12:
2163–8.
5-HT 1A and 5-HT1B agonists for dyskinesia Brain (2008) Page15 of15
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
6
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 